Overview

A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and effectiveness of two dosage schedules for ISIS 2922 in the treatment of advanced cytomegalovirus (CMV) retinitis
Phase:
N/A
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.
Treatments:
Fomivirsen